The Filing Desk

UroGen Pharma

URGN · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

URGN · Last close · November 13, 2026
$26.18
Value UroGen Pharma yourself

UroGen Pharma's revenue rose 21.4% to $110 million in fiscal 2025. Its operating margin was −113.7%, down from −107.1% a year earlier. Free cash flow was −$163 million. The diluted share count rose 12.2%.

UroGen Pharma Ltd. Latest fiscal year ended December 31, 2025 10-K filed March 2, 2026 · 0001437749-26-006234 Updated
Revenue
$110M
21.4%
Operating margin
−113.7%
6.7 pts
Net income
−$154M
 
Free cash flow
−$163M
 
Return on equity
—
 
Market cap
$1.3B
Nov 13 close
P/E
—
 

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What UroGen Pharma does

UroGen is a biotechnology company that develops and sells treatments for urothelial and specialty cancers, such as cancers of the lining of the bladder and upper urinary tract. Its technology is RTGel, a gel that is liquid when cold and turns to a gel at body temperature, so a drug stays in the urinary tract for several hours.

It has two approved products, both made of the drug mitomycin in RTGel. Jelmyto treats low-grade upper tract urothelial cancer. Zusduri treats recurrent low-grade intermediate risk non-muscle invasive bladder cancer. Both are designed to destroy tumors without surgery. It earns money by selling them.

It is also working on UGN-501, an investigational virus designed to attack cancer cells. It has a loan from Pharmakon, and under a prepaid forward contract it owes tiered cash payments to RTW based on net sales of its products.

Its biggest risks, as it describes them

  • Needing more financing, and diluting shareholders or giving up rights to its technology if it raises it.
  • Depending heavily on the success of its two approved products, Jelmyto and Zusduri.
  • Debt from its loan with Pharmakon and covenants under its RTW contract that limit extra borrowing.
  • Results for its drugs in larger, broader groups of patients that may differ from its clinical studies.
  • Raising money may force it to cut back operations or give up product rights.
From UroGen Pharma's annual report on Form 10-K, filed March 2, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

UroGen Pharma lost money in fiscal 2025: a net loss of $154 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red. Where the filings' structured data doesn't give a year's earnings per share, the column is blank.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments67100142242120
Debt incl. finance leases09899124130
Net debt (negative means net cash)−67−2−42−1189
Net debt to EBITDA—————
Debt to equity0.0x————
Interest coverage—————
Current ratio5.1x5.4x5.4x6.0x4.0x
Quick ratio4.9x5.2x5.2x5.8x3.6x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project UroGen Pharma's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

Over the 12 months between November 14, 2025 and November 13, 2026, no insider bought UroGen Pharma shares on the open market, and 2 insiders sold $4.7 million, $1.3 million of it under trading plans set up in advance.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Sep 8, 2026Jason Drew SmithGeneral CounselSold1,519$42.54$64,618Form 4
Sep 8, 2026Mark SchoenbergChief Medical OfficerSold871$42.92$37,383Form 4
Aug 20, 2026Mark SchoenbergChief Medical OfficerSold60,677$47.05$2.9 millionForm 4
Jul 9, 2026Mark SchoenbergChief Medical OfficerSold plan10,000$40.00$400,000Form 4
Jun 22, 2026Mark SchoenbergChief Medical OfficerSold plan10,000$35.01$350,100Form 4
Jun 8, 2026Mark SchoenbergChief Medical OfficerSold5,222$27.30$142,561Form 4
May 8, 2026Mark SchoenbergChief Medical OfficerSold plan10,000$30.00$300,000Form 4
Feb 3, 2026Jason Drew SmithGeneral CounselSold7,479$19.69$147,262Form 4
Feb 3, 2026Mark SchoenbergChief Medical OfficerSold7,373$19.69$145,174Form 4
Nov 19, 2025Mark SchoenbergChief Medical OfficerSold plan10,000$25.00$250,000Form 4
Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score6 of 95 of 92 of 9
Rule of 40−64.0%−98.1%−126.8%
Altman Z''−10.10−6.22−15.59
Accruals ratio−16.5%−13.0%3.7%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets rosePassPassPass
Cash from operations exceeds net incomePassPassFail
Debt fell relative to assetsPassPassPass
Current ratio rosePassPassFail
Share count didn't riseFailFailFail
Gross margin rosePassPassFail
Revenue rose relative to assetsPassFailFail
F-score6 of 95 of 92 of 9
Companies that report no gross profit are scored on the other eight.

Compare

Put UroGen Pharma side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
UroGen PharmaFY2521.4%−113.7%−148.2%——2
Zevra TherapeuticsFY25350.9%−59.1%−2.3%−218.8%—5Compare
ZymeworksFY2538.9%−87.3%−32.6%———Compare
Nurix TherapeuticsFY2554.0%−340.2%−313.7%———Compare
Eton PharmaceuticalsFY25104.9%−1.1%12.8%−1.9%1.4x4Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue188101248648390110
Revenue growth—−53.5%−86.2%−98.4%65,450.0%307.2%34.0%28.5%9.3%21.4%
Gross profit188−10114357738297
Research and development—193749474853465767
Operating income1−20−77−110−127−92−79−66−97−125
Net income−2−20−76−105−128−111−110−102−127−154
Diluted EPS (US$)−1.91−2.14−4.80−5.12−5.90−4.96————
Diluted shares (millions)2101620222223294348
Cash flow
Cash from operations4−10−37−71−106−85−88−76−97−162
Capital expenditure1010110000
Free cash flow3−10−38−71−107−86−88−77−97−163
Dividends paid0000000000
Share buybacks0000000000
Acquisitions0000000000
Stock-based compensation26313028231191312
Balance sheet at fiscal year end
Cash and short-term investments2173—14710267100142242120
Debt incl. finance leases—————09899124130
Total assets2376104202122120136178286200
Total liabilities77142226111225244294306
Shareholders' equity166890180968−89−65−9−106
Margins and ratios
Gross margin99.8%92.7%−59.8%100.0%91.5%89.3%88.1%88.7%90.2%88.7%
Operating margin4.5%−244.6%−6,842.2%−608,211.1%−1,074.2%−192.1%−122.8%−79.2%−107.1%−113.7%
Net margin−11.1%−245.2%−6,707.2%−584,144.4%−1,088.9%−230.7%−170.6%−123.6%−140.3%−139.8%
Free cash flow margin19.9%−120.6%−3,359.4%−396,344.4%−907.7%−178.3%−136.4%−92.6%−107.4%−148.2%
Rule of 40 (growth + FCF margin)—−174.1%−3,445.6%−396,442.8%64,542.3%128.9%−102.5%−64.0%−98.1%−126.8%
Return on capital——————————
Return on equity—−47.2%−95.4%−77.8%−92.9%−211.6%————
Return on assets—−40.6%−84.5%−68.7%−79.2%−91.7%−86.0%−65.1%−54.7%−63.1%
Net debt to EBITDA——————————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: UroGen Pharma's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with UroGen Pharma.